SKYE
Skye Bioscience, Inc. NASDAQ Listed Nov 26, 2014$0.68
-4.02%
vs $0.71
Mkt Cap $27.0M
52w Low $0.58
2.5% of range
52w High $4.75
50d MA $0.80
200d MA $1.25
P/E (TTM)
—
EV/EBITDA
—
P/B
1.4x
Debt/Equity
0.0x
ROE
-279.3%
P/FCF
-0.6x
RSI (14)
40.70
ATR (14)
$0.06
Beta
2.87
50d MA
$0.80
200d MA
$1.25
Avg Volume
175.5K
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
11250 El Camino Real · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.30 | -0.36 | -21.2% | 0.80 | -17.4% | -9.7% | -2.0% | -6.6% | +8.4% | -6.4% | — |
| Nov 10, 2025 | AMC | -0.33 | -0.32 | +3.0% | 1.42 | -1.4% | +2.8% | +4.1% | -9.9% | -5.1% | +7.7% | — |
| Aug 7, 2025 | AMC | -0.34 | -0.44 | -29.4% | 3.55 | -1.4% | -0.8% | -0.3% | -7.4% | -3.4% | +4.1% | — |
| May 8, 2025 | AMC | -0.31 | -0.28 | +9.7% | 1.79 | +6.1% | +1.1% | +13.3% | -5.4% | -2.1% | +5.8% | — |
| Mar 20, 2025 | AMC | -0.28 | -0.24 | +14.3% | 1.89 | +1.1% | +19.0% | +4.4% | +0.4% | -2.5% | -7.8% | — |
| Nov 7, 2024 | AMC | -0.26 | -0.22 | +15.4% | 5.44 | +9.6% | +5.0% | -3.7% | -2.0% | -1.5% | +3.8% | — |
| Aug 9, 2024 | AMC | -0.20 | -0.20 | +0.0% | 4.52 | -2.7% | +1.8% | -9.8% | +8.4% | +12.0% | -7.5% | — |
| May 10, 2024 | AMC | -0.16 | -0.18 | -12.5% | 11.32 | -1.9% | +0.8% | +6.5% | +4.4% | -3.4% | -1.6% | — |
| Mar 22, 2024 | AMC | -0.38 | -0.63 | -65.8% | 12.00 | +0.0% | +11.7% | +2.8% | +4.1% | +9.1% | -9.3% | — |
| Nov 13, 2023 | AMC | — | -3.17 | — | 1.70 | +0.0% | -7.1% | -8.9% | +6.2% | +13.7% | -2.9% | — |
| Aug 7, 2023 | AMC | — | -0.80 | — | 5.25 | +4.8% | -9.5% | +0.0% | +0.0% | -10.5% | -5.9% | — |
| May 11, 2023 | AMC | — | -2.50 | — | 3.75 | +0.0% | +0.0% | +6.7% | -6.2% | +0.0% | -6.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.87 | $3.19 | +11.1% | +26.1% | +1.9% | +15.2% | -3.3% | +1.7% |
| Mar 21 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $1.89 | $1.91 | +1.1% | +19.0% | +4.4% | +0.4% | -2.5% | -7.8% |
| Mar 21 | Craig-Hallum | Maintains | Buy → Buy | — | $1.89 | $1.91 | +1.1% | +19.0% | +4.4% | +0.4% | -2.5% | -7.8% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.49 | $3.16 | -42.4% | -42.8% | +11.1% | +14.9% | -3.0% | +1.8% |
| Sep 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.49 | $3.16 | -42.4% | -42.8% | +11.1% | +14.9% | -3.0% | +1.8% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.84 | $6.00 | +2.7% | +8.7% | +10.1% | -9.2% | -5.5% | +0.0% |
| Sep 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.06 | $6.03 | -0.5% | -3.6% | +8.7% | +10.1% | -9.2% | -5.5% |
| Aug 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.86 | $6.92 | +0.9% | -9.6% | -2.1% | +5.3% | -3.1% | -4.8% |
| Jul 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.01 | $7.23 | -9.7% | +0.6% | -6.2% | -1.3% | -26.3% | +11.8% |
| Jun 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.86 | $10.79 | -0.6% | -12.4% | -6.1% | -13.0% | +8.1% | -6.2% |
| Jun 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.48 | $10.21 | -2.6% | +3.6% | -12.4% | -6.1% | -13.0% | +8.1% |
| Mar 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.55 | $10.20 | -3.3% | +22.3% | +2.4% | +2.2% | -2.0% | -4.3% |
No insider trades available.
8-K
Skye Bioscience, Inc. -- 8-K Filing
Skye Bioscience has until September 14, 2026 to restore its stock price above Nasdaq's minimum bid requirement or face potential delisting.
Jun 23
8-K · 5.03
! Medium
Skye Bioscience, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
May 29
8-K
Skye Bioscience, Inc. -- 8-K Filing
May 15
8-K
Unknown — 8-K Filing
I cannot write a meaningful one-sentence analysis because the filing summary provided lacks substantive disclosure content—it only contains technical XBRL metadata and schema references without actual business events or financial information.
Apr 6
8-K
Unknown — 8-K Filing
Repricing underwater stock options for 2.4 million shares avoids immediate dilution but signals weak equity performance and may frustrate existing shareholders who see compensation costs shifted rather than eliminated.
Apr 3
8-K
Unknown — 8-K Filing
SKYE risks delisting if it doesn't regain a $1+ stock price within 180 days, potentially causing forced selling and reduced liquidity for shareholders.
Mar 19
8-K
Unknown — 8-K Filing
Skye Bioscience's obesity-treatment pipeline progress and 2026 milestone guidance could validate their GPCR modulation approach, but investors should monitor cash runway and clinical trial results closely given the company's pre-revenue stage.
Mar 10
8-K
Skye Bioscience, Inc. -- 8-K Filing
Skye Bioscience (SKYE) prevailed in a legal dispute with former employee Ms. Arsenault regarding her employment termination and agreement terms.
Feb 20
8-K · 8.01
!! High
Skye Bioscience, Inc. -- 8-K 8.01: Material Event / Announcement
Skye Bioscience reported positive Phase 2a extension study interim results showing 19 participants completed week 26 blinded extension with nimacimab plus semaglutide combination demonstrating sustained treatment tolerability and efficacy signals.
Feb 2
Valuation
Market Cap
$27.0M
Enterprise Value
$1.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.01x
P/B
1.35x
P/S
—
P/FCF
-0.63x
EV/EBITDA
—
Shares Out
39.7M
Financials (TTM)
Revenue
$0
Net Income
-$57.3M
EBITDA
-$56.6M
Free Cash Flow
-$43.1M
Op Cash Flow
-$43.1M
EPS Basic
$-1.41
EPS Diluted
$-1.44
EPS Forward
$-0.96
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$28.3M
Total Liab.
$8.3M
Total Equity
$20.0M
Cash
$25.7M
LT Debt
$84K
Book Value/Sh
$0.50
Debt/Equity
0.01x
Current Ratio
3.30
Quick Ratio
3.30
Returns & Growth
ROE
-279.3%
ROA
-197.5%
ROIC
-286.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-93.2%
Price Returns
2W
-15.0%
1M
-11.8%
3M
+4.1%
6M
-40.8%
12M
-60.8%
Technicals
52W High
$4.75
52W Low
$0.58
50d MA
$0.80
200d MA
$1.25
RSI (14)
40.70
ATR (14)
$0.06
Beta
2.87
Avg Volume
176K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$21.00
Low
$2.00
Median
$15.00
Data updated apr 27, 2026 1:30am
· Source: financialmodelingprep.com